Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stephanie Manson"'
Autor:
Stephanie Manson, Fritz Offner, Ira Gupta, Ann Janssens, Peter Hillmen, Chai-Ni Chang, Janusz Kloczko, K Govind Babu, Sebastian Grosicki, Astrid McKeown
Publikováno v:
Acta Oncologica. 55:1115-1120
Patients diagnosed with chronic lymphocytic leukemia (CLL) are usually elderly and frequently have a number of comorbidities. Health-related quality of life (HRQoL) for these patients is of utmost importance and should be taken into consideration whe
Autor:
Mario Petrini, Christian H. Geisler, Marinus H. J. van Oers, Steen Lisby, Mark-David Levin, Kazimierz Kuliczkowski, Sebastian Grosicki, Ira Gupta, Lukas Smolej, Stephanie Manson, Fritz Offner, Vanessa C. Williams, Jennifer Phillips
Publikováno v:
lancet oncology, 16(13), 1370-1379. Lancet Publishing Group
Ofatumumab is a human anti-CD20 monoclonal antibody that has proven efficacy as monotherapy in refractory chronic lymphocytic leukaemia. We assessed the efficacy and safety of ofatumumab maintenance treatment versus observation for patients in remiss
Autor:
Jean-Philippe Suchaud, Bertrand Tehard, Florence Mercier, Nadine Ladarre, Sébastien Clippe, Mathieu Laramas, Laetitia Stefani, Isabelle Ray-Coquard, Françoise Ducimetière, Olivier Collard, Stephanie Manson, Jean-Yves Blay
Publikováno v:
BMC Cancer
Background The French EMS study prospectively collected exhaustive data from STS patients diagnosed in the Rhone-Alpes region from 2005 to 07. Methods The database included diagnosis/histology, surgery, radiotherapy, systemic treatments and treatment
Autor:
Saskia Litière, Stephanie Manson, Andrew Bottomley, Judith B. Prins, Ian Judson, Jean-Yves Blay, Sandrine Marreaud, Iwona Lugowska, Winette T. A. van der Graaf, Rachel Hodge, Roberta Sanfilippo, Sant P. Chawla, Corneel Coens
Publikováno v:
Cancer, 121, 17, pp. 2933-41
Cancer, 121, 2933-41
Cancer, 121, 2933-41
Contains fulltext : 152958.pdf (Publisher’s version ) (Open Access) BACKGROUND: Health-related quality of life (HRQoL) was an exploratory endpoint in the PALETTE trial, a global, double-blind, randomized, phase 3 trial of pazopanib 800 mg versus pl